On 8 November 2026, HX BLDG MAT (06655.HK) proposed FX hedging, margin capped at RMB 1.18 billion and daily contracts at RMB 7.875 billion, for a Brazil deal.
On 6 November 2026, AIROBO PLATFORM (00419.HK) launched robot operations platform 2.0, detailing seven systems, 47 modules and 393 functions across brands.
This week's Going Global Weekly covers 18 developments, with pharmaceutical licensing and registration and overseas financing forming the two main threads. On licensing, QYUNS-B granted the global rights to its TL1A/IL-17 bispecific programme to Caldera, while CSTONE PHARMA-B is collaborating with Kimia on a DDR pathway candidate and will lead Phase I trials in China and Australia; on registration, two HUTCHMED products made progress in the United States, Europe and Japan, CMS obtained Singapore approval for a vitiligo topical and ALPHAMAB-B's ADC received FDA clearance for clinical trials. On financing, SIGMASTAR obtained a filing for overseas issuance, ADASPACE, XINDE SEMI, DENGLIN and RELYEZ ENERGY advanced their Hong Kong offerings, METASURFACE completed a Singapore placement and HEMAY delayed its offering. On M&A and orders, MMG's Brazilian nickel acquisition was extended to the end of December and CHALCO signed a RMB 6.55557 billion EPC contract in Guinea.
On 6 November 2026, CMOC (03993.HK) unveiled an A-share buyback of RMB 1-2 billion at up to RMB 22.78 per share over three months, or 0.21%-0.41% of capital.
On 6 November 2026, JIUMAOJIU granted 46,570,000 share options to 128 eligible persons at HKD0.935, about 3.48% of its issued shares excluding treasury shares.
On 6 November 2026, TIME INTERCON said its board approved buying back up to HKD500 million of its shares over 24 months, funded from internal resources.
On 6 November 2026, HUANENG POWER said the Huaneng Coal Power REIT listed in Shanghai under code 508081 after raising RMB3.198 billion net at RMB3.198 per unit.
On 6 November 2026, CSPC PHARMA said the Phase I/II trial of SYS6055, an in vivo CAR-T therapy for B-cell lymphoma, started at its first site in China.
On 6 November 2026, MICROTECH MED-B said the Exchange approved listing of 250,087,968 H shares under full circulation on 5 November, pending conditions.
On 6 November 2026, DIAGENS-B signed a three-year strategic pact with Yongjiang Laboratory to advance medical imaging AI training and use in Guangxi, China.
On 6 November 2026, CSPC PHARMA said the Phase II trial of SYH9061, a nintedanib dry powder inhaler for idiopathic pulmonary fibrosis, started in China.
On 6 November 2026, CHALCO said its board approved an RMB6.55557 billion EPC contract with CHALIECO for the Guinea alumina project, a connected transaction.
On 6 November 2026, GF SEC said its two 2025 sixth tranche bond tranches totalling RMB4.47 billion will pay interest on 10 November at 1.84% and 2.03%.
On 6 November 2026, SHANDONG XINHUA said it obtained China's drug registration certificate for ketorolac tromethamine injection, a Class 3 chemical drug.
On 6 November 2026, CHINA SUNTIEN said NAFMII accepted the registration of its RMB3 billion medium-term notes, valid for two years from 3 November 2026.
On 6 November 2026, VIRTUAL MIND said chairman Mei Weiyi bought 552,000 shares of the Company on market, raising his holding to 25,342,000 shares, or 2.31%.
